Who Generates More Revenue? Corcept Therapeutics Incorporated or Ionis Pharmaceuticals, Inc.

Biotech Revenue Battle: Corcept vs. Ionis

__timestampCorcept Therapeutics IncorporatedIonis Pharmaceuticals, Inc.
Wednesday, January 1, 201426551000214161000
Thursday, January 1, 201550286000283703000
Friday, January 1, 201681321000346620000
Sunday, January 1, 2017159201000507666000
Monday, January 1, 2018251247000599674000
Tuesday, January 1, 20193064860001123000000
Wednesday, January 1, 2020353874000729000000
Friday, January 1, 2021365978000810000000
Saturday, January 1, 2022401858000587000000
Sunday, January 1, 2023482375000787647000
Loading chart...

Unlocking the unknown

Revenue Race: Corcept vs. Ionis

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Corcept Therapeutics Incorporated and Ionis Pharmaceuticals, Inc. have been vying for dominance. From 2014 to 2023, Ionis consistently outpaced Corcept, generating nearly double the revenue in some years. For instance, in 2019, Ionis's revenue was approximately 1.1 billion, nearly 3.7 times that of Corcept's 306 million. However, Corcept has shown impressive growth, with its revenue increasing by over 1,700% from 2014 to 2023. In contrast, Ionis's revenue grew by about 268% during the same period. This data highlights the dynamic nature of the biotech industry, where strategic innovation and market adaptation are crucial. As both companies continue to evolve, investors and industry watchers will be keenly observing their financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025